Stocks / Healthcare

OraSure Technologies Inc

OSUR Stock Report
Current Price
XXXX
Analyst Target Price
$6.00
Market Cap
XXXX
Updated
August 31, 2025
Analysts
4

OraSure Technologies Inc Stock Overview

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internation… More details ➜
1 Year Price Range
Low $2.36 Current High $4.60
PinkLion Scores

Fundamentals Summary

P/E Ratio
-
P/S Ratio
1.75x
Net Income
Revenue
Market Cap

Net Income & Revenue

Last Reported Earnings
June 30, 2025
Earnings per share (EPS) $-0.68
Gross Margin 40.67%
Net Profit Margin -36.84%
Debt/Equity Ratio -46.76%

Dividends

Current Dividend Yield
-
Payout Ratio
-
Forward Dividend Yield
-

Price History

Track historical stock performance, price trends, and volatility for OSUR to see how the stock has performed over time.
YTD
1 Year
5 Years
All

Valuation Summary

We estimate a fair price for OSUR by projecting its future cash flows and discounting them back to today with a XXXXX model.

About the Company

IPO Date
November 12, 1986
Employees
501
Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
USA
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is h